Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Monday’s trading has closed, but ICPT is being traded in the after-hours session. After-Hours quote »
Delayed Data
As of 3:59pm ET
 +2.00 / +0.68%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Intercept Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It focuses on the discovering, developing and commercializing of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. It develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. Intercept Pharmaceuticals was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Contact Information

Intercept Pharmaceuticals, Inc.
450 West 15th Street
New York New York 10011
P:(646) 747-1000
Investor Relations:



Mutual fund holders46.26%
Individual stakeholders40.16%
Other institutional24.23%

Top Executives

Mark E. PruzanskiPresident, Chief Executive Officer & Director
Barbara Gayle DuncanChief Financial Officer, Secretary & Treasurer
David A. ShapiroChief Medical Officer & EVP-Development
Luciano AdoriniChief Scientific Officer
Daniel Paul ReganChief Commercial Officer

To view my watchlist

Not a member yet?

Sign up now for a free account